Overview

Webcast ImageWebcast
Q2 2016 Clovis Oncology, Inc. Earnings Conference Call (Replay)
08/08/16 at 4:30 p.m. ET
Q2 2016 Clovis Oncology, Inc. Earnings Conference Call
Monday, August 8, 2016 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicMore >>

Stock Chart
Stock chart for: 03NA000000CLVS
Stock Quote
CLVS (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$22.36
Change (%) Stock is Down 0.67 (2.91%)
Intraday High$24.90
Intraday Low$21.85
Volume13,918,420
Data as of 08/24/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle  
08/23/16FDA Accepts Clovis Oncology’s New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer
Seeking approval for mutant BRCA patients treated with two or more prior therapies FDA Grants Priority Review Status Assigns PDUFA Date of February 23, 2017 BOULDER, Colo.--(BUSINESS WIRE)--Aug. 23, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted Clovis’ New Drug Application (NDA) for accelerated approval of rucaparib and gra... 
Printer Friendly VersionDownload PDF
08/08/16Clovis Oncology Announces Q2 2016 Operating Results and Corporate Update
Rucaparib NDA submission completed in late June for treatment of patients with advanced ovarian cancer with deleterious BRCA mutated tumors FDA decision on filing and determination of PDUFA date is anticipated in late August Rucaparib MAA submission on track for Q4 2016 Rucaparib NDA dataset accepted for an oral presentation at ESMO 2016 Congress in October Clov... 
Printer Friendly VersionDownload PDF
07/26/16Clovis Oncology to Announce Second Quarter 2016 Financial Results and Host Webcast Conference Call on August 8
BOULDER, Colo.--(BUSINESS WIRE)--Jul. 26, 2016-- Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2016 financial results on Monday, August 8, 2016, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis ... 
Printer Friendly VersionDownload PDF
Upcoming EventsMore >>
There are currently no events scheduled.
Receive Email AlertsEmail Alert Icon
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.